会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Cyclic amine compounds as CCR5 antagonists
    • 环胺化合物作为CCR5拮抗剂
    • US07348324B2
    • 2008-03-25
    • US10273111
    • 2002-10-18
    • Shinichi ImamuraShohei HashiguchiTaeko HattoriOsamu NishimuraNaoyuki KanzakiMasanori BabaYoshihiro Sugihara
    • Shinichi ImamuraShohei HashiguchiTaeko HattoriOsamu NishimuraNaoyuki KanzakiMasanori BabaYoshihiro Sugihara
    • A61P31/18A61K31/535A61K31/4965A61K31/44A61K31/47C07D413/00C07D241/00C07D211/00
    • C07D401/12C07D211/58C07D211/62C07D401/14C07D405/14C07D409/14C07D413/14C07D417/14C07D471/04C07D487/14
    • A compound of formula (I) (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R1 and R2 may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N+—R5.Y− (R5 is a hydrocarbon group; Y− is a counter anion); R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G1 is a bond, CO or SO2; G2 is CO, SO2, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G1 is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).
    • 式(I)化合物(其中R 1为氢原子,可被取代的烃基,可被取代的非芳香族杂环基,R 2 O 2 >可以被取代的烃基,可以被取代的非芳族杂环基,或者R 1和R 2可以彼此结合形成A至 形成可以被取代的杂环基; A是N或N + - - - - - - - (R 5) SUP>为烃基; Y为 - 抗衡阴离子); R 3为可被取代的环状烃基或可被取代的杂环基; n 为0或1; R 4为氢原子,可被取代的烃基,可被取代的杂环基,可被取代的烷氧基,可被取代的芳氧基 ,或可以被取代的氨基,E是可以是二价脂族烃基 被除氧基以外的基团取代; G 1是一个键,CO或SO 2; G 2是CO,SO 2,NHCO,CONH或OCO; J为次甲基或氮原子; 并且Q和R中的每一个是可被取代的键或二价C 1-3烷基脂族烃; 条件是当G 2 O是OCO时J为次甲基,当另一个为键并且Q和R各自不被氧代基取代时,Q和R中的一个不为键, 当G 1是一个键时)或其盐具有强的CCR5拮抗活性,并且可以有利地用于治疗或预防人类各种HIV感染性疾病(如艾滋病)。
    • 2. 发明授权
    • Process for assembling piping or components by TIG welding
    • 通过TIG焊接组装管道或部件的工艺
    • US5396039A
    • 1995-03-07
    • US156817
    • 1993-11-24
    • Henri ChevrelTaeko HattoriHideki TakagiEiichi OzawaJean-Marie Friedt
    • Henri ChevrelTaeko HattoriHideki TakagiEiichi OzawaJean-Marie Friedt
    • B23K9/16B23K9/028B23K9/167B23K9/23B23K9/00
    • B23K9/0286
    • A process to avoid or limit corrosion at the junction of two piping comprising devices welded together, said piping comprising devices being adapted to flow corrosive gases through them, said process comprising the steps of:a) providing a first piping comprising device and connecting it to an inert gas source;b) purging it with an inert gas comprising substantially not more than 10 ppb of an oxidizing gas selected from the group consisting of oxygen, carbon dioxide, water vapor or mixtures thereof, said inert gas flowing from a first opening to a second opening of said piping comprising device;c) providing a second pipe comprising device in flow communication with the first one, while continuing to purge the first piping comprising device;d) welding the two piping comprising devices, said welding being carried out under an inert gas atmosphere; ande) repeating steps c and d if necessary.
    • 一种避免或限制在包括焊接在一起的装置的两个管道的接合处的腐蚀的过程,所述管道包括适于使腐蚀性气体通过它们的装置,所述方法包括以下步骤:a)提供包括装置的第一管道并将其连接到 惰性气源; b)用惰性气体吹扫,所述惰性气体基本上不超过10ppb的选自氧,二氧化碳,水蒸气或其混合物的氧化气体,所述惰性气体从第一开口流到所述 管道包括装置; c)提供包括与第一管流动连通的装置的第二管道,同时继续吹扫包括第一管道装置的第一管道; d)焊接包括装置的两个管道,所述焊接在惰性气体气氛下进行; 和e)如果需要,重复步骤c和d。
    • 3. 发明授权
    • Kaleidoscope and image material assembly for kaleidoscope
    • 万花筒和图像材料装配万花筒
    • US07101046B2
    • 2006-09-05
    • US10641223
    • 2003-08-13
    • Keiji HattoriTaeko Hattori
    • Keiji HattoriTaeko Hattori
    • G03B21/00G02B27/08
    • G02B27/08
    • A kaleidoscope includes a kaleidoscope body assembled in the shape of a sleeve so as to locate surfaces of mirrors therein and a support body, having two concave parts, attached to an end portion of the kaleidoscope body and supporting an image material assembly at the end portion. A retaining member is attached to one of the support body, the end portion of the kaleidoscope body and a part adjacent the support body and kaleidoscope body, to prevent the image material assembly from falling from an opening end of the concave parts. The image material assembly is supported rotatably and detachably by the support body so that it can change from the image material assembly attached in the kaleidoscope body to a different image material assembly.
    • 万花筒包括组装成套筒形状的万花筒体,以便将镜子的表面定位在其中,并具有一个支撑体,该支撑体具有两个凹形部分,其连接到万花筒主体的端部并在该端部支撑图像材料组件 。 保持构件附接到支撑体,万花筒体的端部和与支撑体和万花筒主体相邻的部分中的一个,以防止图像材料组件从凹部的开口端落下。 图像材料组件由支撑体可旋转地和可拆卸地支撑,使得其可以从附接在万花筒体中的图像材料组件改变成不同的图像材料组件。
    • 4. 发明授权
    • Cyclic amine compounds as CCR5 antagonists
    • 环胺化合物作为CCR5拮抗剂
    • US06562978B1
    • 2003-05-13
    • US10089374
    • 2002-03-29
    • Shinichi ImamuraShohei HashiguchiTaeko HattoriOsamu NishimuraNaoyuki KanzakiMasanori BabaYoshihiro Sugihara
    • Shinichi ImamuraShohei HashiguchiTaeko HattoriOsamu NishimuraNaoyuki KanzakiMasanori BabaYoshihiro Sugihara
    • C07D21128
    • C07D401/12C07D211/58C07D211/62C07D401/14C07D405/14C07D409/14C07D413/14C07D417/14C07D471/04C07D487/14
    • A compound of formula (I) (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R1 and R2 may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N+—R5.Y−(R5 is a hydrocarbon group; Y− is a counter anion); R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G1 is a bond, CO or SO2; G2 is CO, SO2, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G1 is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).
    • 式(I)的化合物(其中R 1为氢原子,可被取代的烃基,可被取代的非芳族杂环基,R 2为可被取代的烃基,非芳香族杂环基 或者R 1和R 2可以与A相互结合形成可被取代的杂环基; A是N或-N + -R 5 .Y-(R 5是烃基; Y-是抗衡阴离子 ); R3是可以被取代的环状烃基或可以被取代的杂环基; n是0或1; R4是氢原子,可以被取代的烃基,可以被取代的杂环基, 可被取代的烷氧基,可被取代的芳氧基或可被取代的氨基,E是可被除氧以外的基团取代的二价脂族烃基; G 1是键,CO 或SO 2; G2是CO,SO 2,NHCO,CONH或OCO; J是次甲基或硝基 原子 Q和R分别为可以被取代的键或二价C 1-3脂族烃; 条件是当G2是OCO时J是次甲基,当另一个是键时Q和R中的一个不是键,并且当G 1是键时,Q和R各自不被氧代基取代)或 其盐具有有效的CCR5拮抗活性,可有利地用于治疗或预防人类各种HIV感染性疾病(如艾滋病)。